Metrics cut 1
- FY30 revenue target of INR 1 billion deferred; now viewed as aspiration, clarity expected by December (prior guidance: INR 1 billion sales by FY30)
Event Participants
Executives
5 Himanshu Agarwal, Amrit Singh, Gunjan Singh, Yann D'Herve, Umang Vohra
Analysts
5 Bansi Desai, Foram Parekh, Kunal Dhamesha, Shreya Chatterjee, Shyam Srinivasan
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | $4.223 million | Down 23% YoY; impacted by shipment phasing in Pharma CDMO, softer AgChem, low formulation revenue, partly offset by strong Sapala growth and resilient API performance |
| Gross Margin | 71.5% | Declined from 73% in Q1 FY26; reflected product mix, lower contribution from high-margin Pharma CDMO, and higher freight/logistics/raw material costs, partly mitigated by price pass-through |
| Adjusted EBITDA | $92 million | Margin of 2.2%; reduction driven by lower revenue base, negative operating leverage, and subsidiary consolidation impact (primarily NJ Bio losses) |
| Standalone Revenue | $35.99 million | Generated adjusted EBITDA of $332 million at 9.2% margin; materially stronger operating position than consolidated |
| Sapala Revenue | $274 million | Grew 2.5x YoY while maintaining strong EBITDA margin; supply commenced under specialized nucleic acid building blocks program |
| NJ Bio Revenue | $350 million | Below internal expectations; recorded adjusted EBITDA loss of $328 million, significantly weighing on consolidated profitability |
| CapEx | INR 598 million | Invested in capabilities required for future growth |
| Net Cash | INR 2,512 million | Balance sheet remains resilient as of 30th June 2026 |
| Pharma CDMO Revenue Growth | -38.7% YoY | Q1 affected by customer shipment phasing; commercial vs development share at 57%/43% |
| Specialty Chemicals Revenue Growth | -34.7% YoY | AgChem declined as FY27 expected to be H2-skewed due to season-led phasing |
Geographic & Segment Commentary
Pharma CDMO: Q1 revenue declined 38.7% YoY due to shipment phasing, but portfolio progressed with two molecules moving into commercial supply, restocking order secured for one destocked commercial molecule, and RFQ pipeline strengthening with phase III and commercial inquiries from large pharma. Commercial OTIF remained at ~100% year-to-date. ADC payload business saw positive customer feedback on commercial KSM program with additional audits completed successfully; MMAE and exatecan gaining traction as alternatives to Chinese suppliers. NJ Bio released another GMP ADC batch and operationalized an additional GMP lab at Princeton, but remains watchful of biotech funding environment affecting FC renewals.
API Plus: API business remained resilient, performing slightly ahead of internal expectations with favorable pricing and improved product mix. Secured two CEP approvals, filed two Korean DMFs, targeting seven new API filings for FY27. Portfolio increasingly focused on niche CNS and controlled substances assets with inherent entry barriers. Formulation business was slightly below expectations due to API production delay, lower demand for mature product, and customer-led pack configuration change. Nacharam remediation progressing with CAPA implementation on track and product supplies resumed.
Specialty Chemicals: Q1 declined 34.7% YoY primarily due to H2-dominated phasing in AgChem CDMO. Performance materials delivered growth with photochromic portfolio balanced; OLED materials new business activity improving. A confirmed active ingredient program with existing global innovator entered registration process during Q1. Medium-term objective is to qualify approximately two new products annually with anchor customers and new customers across Europe and Japan. Automation and operating upgrades across network will support transition to innovator product-led business.
Company-Specific & Strategic Commentary
Integrated Nucleic Acid Business: Anchored in Sapala subsidiary, aligning chemistry, development, manufacturing, and commercial supply into one operating approach. Dr. P.Y. Reddy to lead this combined business through FY 2030 with clear path to full ownership by then. Capital deployed selectively for new amidites facility and expanding oligonucleotide capabilities.
AgChem Portfolio Revamp: Starting to revamp capacities for next set of agrochemical programs, working towards more integrated organization and clearer governance model. First qualification campaign with two-year Japanese innovator scheduled in FY 2027.
Safety & Quality Systems: Enhanced process safety reviews, automation, closed handling of critical operations, independent site audits. Multiple audits by large innovative partners completed without critical findings. Achieved EcoVadis Gold, strong CDP ratings, SBTi validation, ISO 22301 certification, British Safety Council recognition.
Operational Progress Indicators: Significant restocking orders received for commercial molecules; commercial OTIF at ~100%; CapEx review for another strategic customer progressed positively; flow reactor investment at Jeedimetla site expected ready next quarter.
Pashamylaram Facility Inspection: US FDA completed inspection from 27th July to 5th August; received Form 483 with five observations, none related to data integrity; will respond within stipulated timelines.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Trajectory | Sequential improvement in Q2; return to YoY growth from H2 FY27 | Supported by scheduled commercial program deliveries, restocking order execution, operational normalization, improving utilization |
| EBITDA Margin | FY27 closer to previous year's margin percentage; acceleration from FY28 onwards | Operating leverage to play in as top line increases; pace depends on revenue conversion, mix, utilization |
| Pharma CDMO | Q2 significantly better than Q1; strong H2 performance expected | Restocking order provides meaningful delivery visibility for Q4 FY27 and FY28; newly commercialized programs scheduled for delivery across Q2 and Q3 |
| API Filings | Seven new API filings targeted for FY27 | Portfolio focused on niche CNS and controlled substances; value chain play across intermediates, APIs, pellets, formulations |
| Specialty Chemicals | FY27 year of qualification; double-digit growth from FY28 onwards | Subject to customer qualification and regulatory timelines; two new product qualifications annually targeted |
| Growth Outlook | All three businesses capable of solid growth over next 3+ years | Sapala/oligonucleotides potential to nearly double in 3-4 years; API Plus at 30-40% of potential over 3-5 years |
| INR 1 Billion FY30 Sales Target | Status unclear; management to provide clarity by December | Currently viewed as aspiration; may be "a little bit away" from achieving |
Risks & Constraints
| Risk | Context |
|---|---|
| NJ Bio Profitability Drag | NJ Bio reported revenue of $350 million below expectations with adjusted EBITDA loss of $328 million, significantly weighing on consolidated profitability. Management expects continued impact until revenue conversion improves; cost base needs to align with revenue generation. |
| Biotech Funding Environment | Continuing to influence timing of customer decisions and FC renewals, particularly at NJ Bio. Management remains watchful of this external factor affecting near-term revenue visibility. |
| AgChem Chinese Generic Pressure | Chinese generic competition in AgChem segment is pressuring base business. Management addressing through innovation partnerships and qualification of new products, with FY27 viewed as transition year. |
| Regulatory/Inspection Findings | US FDA Form 483 with five observations at Pashamylaram facility (none data-integrity related). Also, Nacharam remediation ongoing with regulatory engagement; product supplies resumed but full normalization pending. |
| Patent Expirations | Two molecules in commercial portfolio expected patent expiration. Impact already reflected in past two fiscal years as intermediates supplied are for post-patent products; mature node of portfolio has seen decrease. |
Q&A Highlights
Growth Outlook by Business Segment
- Question: How should we think about growth ranges for each business segment over 2-3 years? (Kunal Dhamesha, Macquarie)
- Answer: Sapala/oligonucleotide business has solid chance of nearly doubling in 3-4 years. ADC business needs revenue trajectory to return to amortize cost base. Small molecule CDMO seeing solid reload orders and conversions building for strong H2. API Plus is bedrock business at 30-40% of potential over 3-5 years with steady, sustainable CAGR. AgChem has strong potential to improve profitability with innovator partnerships. (Umang Vohra)
Capital Allocation and Synergies
- Question: How do you think about capital allocation between businesses and what synergies exist? (Kunal Dhamesha, Macquarie)
- Answer: Allocation is not purely by business segment but prioritizes where Cohance has differentiated hook—areas like colored compounds, innovation-partner work. API/CDMO businesses are closer than AgChem/Specialty Chemicals, though synergies exist in shared facilities and common overheads. Some innovator customers span both pharma and AgChem. (Umang Vohra)
CDMO Macro Trends and Differentiation
- Question: How is the macro environment translating into RFQ and order win rates for Indian CDMOs? (Shyam Srinivasan, Goldman Sachs)
- Answer: Geopolitical situation is pushing large pharma and biotech to diversify supply to India; more alignment between India and US for intermediates. This translates into increased RFQs, especially late-stage phase III and commercial. However, clients already have existing sources, so conversion takes longer. (Yann D'Herve)
API Pricing and Growth Drivers
- Question: Are you able to adjust prices upward in response to input costs? (Shyam Srinivasan, Goldman Sachs)
- Answer: Passed on a major chunk of cost escalation through price increases, though mindful of long-term relationships. Growth drivers include new product additions (seven filings this year), life cycle management opportunities with innovators, and value chain play across intermediates, APIs, pellets, and formulations. (Gunjan Singh)
EBITDA Margin Trajectory
- Question: Will normalized margins be materially different from history given new business structure? (Shyam Srinivasan, Goldman Sachs)
- Answer: Margin recovery expected closer to previous year's percentage for current year, with acceleration from FY28 onwards as operating leverage plays in with top line growth. Current quarter has significant operating deleverage given low revenue base. (Himanshu Agarwal)
CDMO Competitive Positioning
- Question: What makes customers choose Cohance over other CDMOs in small molecule space? (Bansi Desai, JPMorgan)
- Answer: Differentiation comes from anchor relationships built over 7-10 years with deep trust, differentiated scientific capability and analytical methods, and cost competitiveness. The science envelope is still being developed but capability, capacity, and hunger exist to compete on science and relationships rather than just cost. (Umang Vohra)
Phase III Pipeline Confidence
- Question: With 10 phase III assets, do we have confidence in high growth over next 2-3 years? (Bansi Desai, JPMorgan)
- Answer: Yes—commercial portfolio has bimodal distribution with freshly approved molecules in growth phase; more than 50% of phase III molecules should get approval. This will feed maturing pipeline and drive near-term growth. (Yann D'Herve)
FY30 Revenue Target
- Question: Do we still retain the INR 1 billion sales target for FY30? (Foram Parekh, BOB Capital Markets)
- Answer: Cannot provide clarity yet; will endeavor to provide by December. Currently viewed as aspiration—company may be "a little bit away" from achieving over next 3-4 years. (Umang Vohra)
Restocking Order Quantification
- Question: How much of the INR 260 crore destocking impact is returning this year? (Foram Parekh, BOB Capital Markets)
- Answer: One of two molecules has confirmed restocking order spread over two years. Early to quantify exactly how much will come in FY27 vs FY28; better clarity expected by end of next quarter's call. (Himanshu Agarwal / Yann D'Herve)
API Plus Segment Mix and Profitability
- Question: Is the 60% segment mix for API Plus sustainable and how is profitability? (Foram Parekh, BOB Capital Markets)
- Answer: Portfolio is differentiated, concentrated in CNS (third fastest-growing segment) and controlled substances with inherent entry barriers. Innovative relationships where Cohance commands >50% global market share for certain products. Margin profile is among top tier in generic API space. Sustained growth backed by new product filings acceleration. (Gunjan Singh)
Key Takeaway
Cohance Lifesciences reported Q1 FY27 consolidated revenue of $4.223 million, down 23% YoY as guided—the "lowest quarter ever"—with adjusted EBITDA margins at 2.2% due to negative operating leverage and NJ Bio's $328 million adjusted EBITDA loss. The company is executing a recovery path: sequential Q2 improvement with return to YoY growth in H2, supported by secured restocking orders, scheduled commercial program deliveries (six intermediates across Q2/Q3), and the customized ADC payload order on schedule. Strategic priorities center on building an integrated nucleic acid business under Sapala (2.5x revenue growth in Q1) with a path to full ownership by FY30, strengthening Safety & Quality systems (audits completed without critical findings, EcoVadis Gold), and transitioning Specialty Chemicals toward innovator-led programs with 2 new product qualifications annually. Management maintained FY27 margin guidance "closer to previous year" with acceleration from FY28, while flagging NJ Bio cost-revenue rebalancing, biotech funding timing, and the US FDA Form 483 (five observations, none data-integrity) as near-term watch points. Long-term, all three business engines are positioned for solid growth over 3+ years, with FY30 revenue target clarity expected by December.